Getinge 2022 Annual Report

Getinge 2022 Annual Report NOTE 2 Net sales per revenue classification SEK M Introduction Strategy Corporate Governance Annual Report Sustainability Report Other information Contents Restated 2022 20211) Restatement¹ 11,101 11,292 -969 2021 12,261 Capital goods Recurring revenue Product sales 11,658 11,000 969 10,031 Service assignments incl. spare parts 5,532 4,757 4,757 Total recurring revenue 17,191 15,757 969 14,787 Total 28,292 27,049 27,049 1) Restatement of the distribution of net sales between capital goods and recurring revenue (product sale) have been made for comparative figures for year 2021. All net sales of DPTE®-BetaBags in Life Science are recognized as recurring revenue (product sale) instead of capital goods as from January 1, 2022. NOTE 3 Segment reporting The segment reporting has been prepared in accordance with the same policies as for the Group in its entirety. Getinge's operations throughout the world are organized into three business areas - Acute Care Therapies, Life Science and Surgical Workflows. These business areas form the basis for the Group's segment information. Business terms and conditions as well as market-regulated pricing apply for delivery of products and services between Group companies. No sales are made between the different business areas. The Group has no single customer that accounts for 10% or more of the Group's sales. The reporting segments are active in the following operations Acute Care Therapies: Acute Care Therapies offers solutions for life support in acute health conditions. The offering includes solu- tions for cardiac, pulmonary and vascular therapies and a broad selection of products and therapies for intensive care. Life Science: Life Science offers a comprehensive range of equip- ment, technical expertise and consultation to prevent contam- ination in biopharmaceutical production, biomedical research, medical device manufacturing and laboratory applications. Surgical Workflows: Surgical Workflows offers products and ser- vices for efficient disinfection and sterilization of instruments used in operations, operating tables and other high-quality hardware for operating rooms and advanced IT systems for efficient and secure hospital workflows. SEK M Acute Care Therapies Life Science Surgical Workflows Group functions Total Interest income and other similar income Interest expenses and other similar expenses Tax on profit for the year Net profit Operating profit Amortization, depreciation Net sales Adjusted EBITA (EBIT) and write-downs 2022 2021 2022 2021 2022 2021 2022 2021 15,285 15,527 3,402 4,444 2,889 3,685 -1,233 -1,057 4,026 3,558 650 729 600 702 -176 -166 8,981 7,965 549 390 480 369 -608 -578 -320 -351 -343 -386 -10 -13 28,292 27,049 4,281 5,212 3,626 4,371 -2,027 -1,814 141 10 -295 -193 -956 -1,187 2,516 3,000 Assets Liabilities Investments SEK M 2022 2021 2022 2021 2022 2021 Acute Care Therapies Life Science 32,611 28,909 7,704 7,242 855 708 3,413 2,881 1,318 1,125 69 57 Surgical Workflows Total business areas 9,284 7,473 2,991 2,402 212 165 45,308 39,263 Undistributed Total 6,724 5,292 52,032 44,555 12,013 10,769 9,565 21,578 1,136 930 8,610 19,379 1,136 930 84 =4

View entire presentation